<DOC>
	<DOCNO>NCT01225744</DOCNO>
	<brief_summary>A Phase II trial demonstrate response rate , use Response evaluation criterion solid tumour ( RECIST ) criterion , patient locally advance / metastatic colorectal cancer treat combination irinotecan , oxaliplatin , UFT cetuximab . ENDPOINTS Primary : Objective response rate ( RECIST ) Secondary : Progression free survival ( PFS ) , Overall survival ( OS ) Toxicity ( CTCAE ) , Resectability liver , lung pelvic disease chemotherapy , Time progression ( TTP ) . POPULATION : The trial aim recruit 50 patient inoperable , metastatic colorectal cancer ELIGIBILITY : Histologically confirm colorectal adenocarcinoma Normal haematology adequate renal liver function Written inform consent able attend follow-up least 3 month TREATMENT 4 weekly cycle chemotherapy alternate irinotecan ( day 1 ) oxaliplatin ( day 15 ) . Cetuximab every 2 week oral UFT Leucovorin 3 week every 4 week . DURATION First patient recruit April 2009 . Accrual take place 24 month Follow-up continue death minimum 3 year</brief_summary>
	<brief_title>Erbitux Study CPT11 , Oxaliplatin , UFToral Targeted Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm adenocarcinoma colon rectum . Patients must mutation Kras Inoperable metastatic locoregional disease ( synchronous recurrence ) No previous chemotherapy establish metastatic disease ( adjuvant chemotherapy must complete 6 month prior trial entry ) Measurable evaluable disease Bone marrow function : neutrophil count &gt; 1.5 x109/l platelet count &gt; 150 x109/l Hepatobiliary function : serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) ; ALP &lt; 5 x ULN ; transaminase ( AST ALT ) &lt; 3 x ULN . ( ≤ 5 liver mets present ) Renal function : estimate creatinine clearance &gt; 50 ml/min , measure Glomerular filtration rate ( GFR ) ( EDTA creatinine clearance ) normal range ECOG performance status 01 consider fit able undergo possible treatment For woman childbearing potential negative pregnancy test require adequate contraceptive precaution sheath partner must use For men adequate contraception sheath must use Patients must give write , inform consent Life expectancy ≥ 3 month . Patients Kras mutation Concurrent uncontrolled medical illness , previous current malignant disease likely interfere protocol treatment comparison Partial complete bowel obstruction Prior EGFR antibody therapy Age &lt; 18 Chronic diarrhoea inflammatory bowel disease Known Pyruvate Dehydrogenase Phosphatase ( DPD ) deficiency Gilbert 's syndrome congenital abnormality biliary transport Previous transplant surgery , require immunosuppressive therapy Regular / uncontrolled angina cardiac arrhythmia Clinically relevant coronary artery disease . History Myocardial infarction last 12 month Previous investigational agent last 4 week Metastatic disease brain Any pregnant lactating woman Patients receive therapy haloginated antiviral drug ( eg : sorivudine ) Patients experience lifethreatening toxicity fluoropyrimidines treatment Patients suffer condition may affect absorption UFT folinic acid . Patients known deficiency inhibitor cytochrome P450 2A6 Patients previously radiotherapy abdomen pelvis last 6 month Any medical psychological condition opinion investigator would enable patient complete study knowingly give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>